These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 30825694)

  • 1. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
    Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
    Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study.
    Turpie AGG; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Ageno W
    Thromb Res; 2017 Jul; 155():23-27. PubMed ID: 28477534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
    Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
    Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
    Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
    Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies.
    Haas S; Mantovani LG; Kreutz R; Monje D; Schneider J; Zell ER; Tamm M; Gebel M; Bugge JP; Ageno W; Turpie AGG
    Res Pract Thromb Haemost; 2021 Mar; 5(3):426-438. PubMed ID: 33870028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Turpie AGG
    TH Open; 2017 Jun; 1(1):e33-e42. PubMed ID: 31259294
    [No Abstract]   [Full Text] [Related]  

  • 8. Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis.
    Mantovani LG; Haas S; Kreutz R; Folkerts K; Gebel M; Monje D; Schneider J; van Eickels M; Sahin K; Zell E; Ageno W; Turpie AGG
    Eur J Intern Med; 2019 Mar; 61():29-33. PubMed ID: 30342973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Haupt V; Schneider J; Turpie AG
    Thromb J; 2014; 12():16. PubMed ID: 25093014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
    Keller L; Marten S; Hecker J; Sahin K; Tittl L; Beyer-Westendorf J
    Int J Cardiol; 2018 Apr; 257():276-282. PubMed ID: 29506708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
    Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
    Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
    Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study.
    Min SK; Kim JS; Kim JY; Park UJ; Lee T; Kang JM; Park SC; Choi WI; Park KH; Gebel M
    Vasc Specialist Int; 2022 Dec; 38():33. PubMed ID: 36573027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD-VTE patients.
    Haas S; Ageno W; Weitz JI; Goldhaber SZ; Turpie AGG; Goto S; Angchaisuksiri P; Dalsgaard Nielsen J; Kayani G; Zaghdoun A; Farjat AE; Schellong S; Bounameaux H; Mantovani LG; Prandoni P; Kakkar AK
    J Thromb Haemost; 2019 Oct; 17(10):1694-1706. PubMed ID: 31220403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on real-world evidence for the treatment of DVT: XALIA.
    Ageno W; Turpie AG
    Thromb Haemost; 2016 Sep; 116(Suppl. 2):S41-S49. PubMed ID: 27623684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.